UPDATE ARTICLE

Pediatric anxiety disorders: from neuroscience to evidence-based clinical practice

Giovanni Abrahão Salum,1,2,3 Diogo Araújo DeSousa,1 Maria Conceição do Rosário,3,4 Daniel Samuel Pine,5 Gisele Gus Manfro1,2,3

1Anxiety Disorders Outpatient Program for Child and Adolescent Psychiatry, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. 2Graduate Program in Medical Sciences: Psychiatry, UFRGS, Porto Alegre, RS, Brazil. 3National Science and Technology Institute for Developmental Psychiatry for Children and Adolescents (INCT), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). 4Child and Adolescent Psychiatry Unit, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil. 5National Institutes of Mental Health (NIMH), Intramural Research Program, Emotion and Development Branch.

The objective of this narrative review of the literature is to describe the epidemiology, etiology, pathophysiology, diagnosis, and treatment of pediatric anxiety disorders. We aim to guide clinicians in understanding the biology of anxiety disorders and to provide general guidelines for the proper diagnoses and treatment of these conditions early in life. Anxiety disorders are prevalent, associated with a number of negative life outcomes, and currently under-recognized and under-treated. The etiology involves both genes and environmental influences modifying the neural substrate in a complex interplay. Research on pathophysiology is still in its infancy, but some brain regions, such as the amygdala and the prefrontal cortex, have been implicated in fear and anxiety. Current practice is to establish diagnosis based purely on clinical features, derived from clinical interviews with the child, parents, and teachers. Treatment is effective using medication, cognitive behavioral therapy, or a combination of both. An introduction to the neuroscience behind anxiety disorders combined with an evidence-based approach may help clinicians to understand these disorders and treat them properly in childhood.

Keywords: Child; adolescent; anxiety disorders; obsessive-compulsive disorder

Introduction

Pediatric anxiety disorders refer to a collection of syndromes characterized by dysfunctional fear and/or anxiety affecting children and adolescents. Fear can be defined as a negative emotional state triggered by the presence of a stimulus that has the potential to cause immediate harm, while anxiety can be defined as an emotional state in which the threat is not immediately present but is anticipated. Both of these emotions are adaptive and essential for survival. They are accompanied by cognitive representations, physical symptoms, and behavioral modifications that prepare the individual to deal with danger (fear response). Fear and anxiety are considered dysfunctional when intensity, duration, and/or frequency are not proportional to the eliciting threat, and thereby cause interference, disabilities, impairment, and/or distress that are judged clinically excessive.

Anxiety disorders in childhood and adolescence are associated with a variety of negative outcomes, including lower educational achievement and failure to attend university.1 They affect children’s functioning with peers, school personnel, and family,2,3 are associated with general psychosocial impairment and disabilities,4 as well as with childhood suicide risk even when they are present in subthreshold levels.4 Pediatric anxiety disorders can also persist and continue to create interference as the child matures into early adulthood, especially when associated with depression.5 Later in life, anxiety disorders are associated with poorer quality of life,6 suicide,7 and increased mortality due to cardiovascular disease,8 generating a high societal burden and costs.9 Despite high prevalence and associations with various negative outcomes, childhood anxiety is rarely recognized by parents and children as a medical problem, leading a minority of affected individuals to receive the care they need.10,11 Furthermore, physicians can fail to recognize pediatric anxiety in children who do present for care, and even when anxiety is recognized, it is frequently treated sub-optimally.9,12,13

The objective of this review was to describe the epidemiology, etiology, pathophysiology, diagnosis, and treatment of pediatric anxiety disorders. Given the fact that anxiety disorders more often co-occur and given the amount of similarities among these syndromes, this paper broadly discusses ideas that are relevant to anxiety disorders as a group.14 Moreover, when considering individual conditions, the review focuses in depth on four specific disorders: separation anxiety (SeAD), social
anxiety (SoAD), generalized anxiety (GAD), and panic (PD) disorders. Evidence related to specific phobias (SPs), obsessive-compulsive (OCD), and posttraumatic stress (PTSD) disorders, when relevant, is also incorporated though in less detail.

Epidemiology

Prevalence

Anxiety disorders as a group constitute the most common mental health problem in childhood and adolescence, affecting from 2.5 to 30% of youths. Large variations in prevalence rates are observed among studies. While the exact reasons for such variations remain unclear, most experts attribute them to methodological factors such as cross-study differences in the age of subjects, assessment instruments, information source, diagnostic system used, or variations in the application of the diagnostic criteria. Nevertheless, cross-cultural variability in prevalence rates for anxiety is also likely to occur, given large differences in risk factor profiles and cultural beliefs. One reasonable estimate for the global prevalence of any anxiety disorder in the age range of 3 to 17 years, adjusted for differences in methodological factors, is 7.2%. There is no nationally representative study for pediatric anxiety in Brazil. The available studies are limited to cities in the South and Southeast, where reported prevalence is approximately 5%. Prevalence for each anxiety disorder is heavily dependent on the age range of the sample and on the age of onset patterns of each disorder. SeAD and SP have the earliest age of onset, with half of the cases emerging before ages 5 and 8, respectively. SoAD and OCD typically emerge at early adolescence, with half of the cases emerging before ages 12 and 14, respectively. GAD is also common in early adolescence and less well studied than the other disorders, due to changes in diagnostic criteria over time. Nevertheless, current data place the median age of onset in late adolescence, by the ages of 16-18 years. Agoraphobia, PD and PTSD are low prevalence conditions in childhood, with higher prevalence rates in late adolescence and early adults (median age of onset 17, 19 and 22, respectively). Beyond data on age trends, anxiety disorders have also been linked to other demographic factors. Gender is probably the most frequent demographic correlate of pediatric anxiety. The female/male gender ratio for almost all anxiety disorder is 2:1 to 3:1. Most studies have shown an association between anxiety and lower instruction levels and worse socioeconomic status but no association has been found with urbanization or ethnicity. Table 1 depicts the prevalence found in two Brazilian studies and other two representative samples in the United States and Europe.

Natural course

Prospective studies have shown that 60-80% of adults with full criteria for anxiety disorders report signs of earlier, pediatric anxiety. Despite the fact that most affected adults have signs of anxiety as children, in children followed prospectively, anxiety disorders have variable natural course. This course typically involves one of four trajectories: 1) spontaneous long-term remission (e.g., childhood SeAD that totally disappears in an otherwise typically developing adolescent who matures to become a healthy adult); 2) strict homotypic continuity (e.g., SoAD in childhood persisting into SoAD in adulthood); 3) broad homotypic continuity (e.g., SeAD in childhood predicting PD in adulthood); and 4) sequential heterotypic comorbidity (e.g., SoAD in childhood predicting heterotypic comorbidity (e.g., SeAD in childhood predicting heterotypic comorbidity (mainly with major depression and substance abuse)).

Etiology and pathophysiology

Mental disorders reflect individual differences in brain function. Those differences are a result of a complex combination of factors that ultimately represent the distal effects of risk genes and/or environmental components (etiological factors). These etiological risk factors act on neural circuits (neural substrates) during brain development and cause quantitative and/or qualitative abnormalities in brain functions (pathophysiological processes). This deviation from typical trajectories of brain development results in emotional and behavioral manifestations of psychiatric disorders.

Genes and environment

Family studies have shown that anxiety disorders are familial, whereas twin studies demonstrated that anxiety disorders are heritable and that the proportion of the phenotypic variability explained by genetic factors (heritability) for anxiety disorders ranges from 25-60%.

In general, this represents modest heritability for a psychiatric condition, clearly meaningful but lower than for highlyheritable conditions, such as attention deficit hyperactivity disorder (ADHD) or autism. In addition, one study investigating common childhood psychiatric disorders found that a general set of genes might nonspecifically influence risk for childhood psychiatric disorders,
### Table 1: Diagnostic criteria for pediatric anxiety disorders and epidemiology

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
<th>Prevalence (%)</th>
<th>Age of onset</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Simplified DSM-IV diagnostic criteria</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generalized anxiety disorder (GAD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Anxiety and excessive worry, most of the days, about a number of events for at least 6 months.</td>
<td>TAU: 0.4</td>
<td>EDS: 19 years</td>
</tr>
<tr>
<td>B - Worry is difficult to control.</td>
<td>PEL: 1.4</td>
<td></td>
</tr>
<tr>
<td>C - At least one of the following: 1) restlessness; 2) easily fatigued; 3) difficulty concentrating or mind going blank; 4) irritability; 5) muscle tension; 6) sleep disturbance.</td>
<td>EDS: 0.8</td>
<td></td>
</tr>
<tr>
<td>Social anxiety disorder (SoAD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Marked and persistent fear of social or performance situations when exposed to unfamiliar people or potential humiliation/embarrassment (must occur with peers, not just with adults).</td>
<td>TAU: 0.7</td>
<td>EDS: 12.5 years</td>
</tr>
<tr>
<td>B - Exposure to the feared social situation provokes anxiety (e.g., crying, tantrums, freezing, or shrinking).</td>
<td>PEL: 0.1</td>
<td></td>
</tr>
<tr>
<td>D - Social or performance situations are avoided or faced with intense anxiety or distress.</td>
<td>NCS: 9.1</td>
<td></td>
</tr>
<tr>
<td>F - At least 6 months.</td>
<td>EDS: 3.5</td>
<td></td>
</tr>
<tr>
<td>Separation anxiety disorders (SeAD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Excessive anxiety when away from home or from attachment figures or when separation is anticipated, with at least three of the following: 1) distress; 2) worry about losing or harm befalling attachment figures; 3) worry that an untoward event will lead to separation; 4) reluctance/refusal to go to school or elsewhere; 5) fearful/reluctant to be alone or without attachment figures; 6) reluctance/refusal to go to sleep without an attachment figure or to sleep away from home; 7) nightmares with separation; 8) physical symptoms.</td>
<td>TAU: 1.4</td>
<td>EDS: 4.5 years</td>
</tr>
<tr>
<td>B - At least 4 weeks.</td>
<td>PEL: 0.7</td>
<td></td>
</tr>
<tr>
<td>Panic disorder (PD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Recurrent unexpected panic attacks (i.e., intense anxiety of sudden onset and brief duration), with at least one of them followed by at least 1 month of at least one of the following: 1) concern about additional attacks; 2) worry about the implications/ consequences of the attack; 3) significant change in behavior related to the attacks.</td>
<td>TAU: 0.0</td>
<td>EDS: 18.5 years</td>
</tr>
<tr>
<td>B - Presence or absence of agoraphobia (differential diagnosis for PD with or without agoraphobia).</td>
<td>PEL: 0.0</td>
<td></td>
</tr>
<tr>
<td>Specific phobias (SP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Marked and persistent excessive or unreasonable fear cued by the presence or anticipation of a specific object or situation (e.g., flying, heights, animals, injection, blood).</td>
<td>TAU: 1.0</td>
<td>EDS: 7 years</td>
</tr>
<tr>
<td>B - Exposure to the phobic stimulus provokes anxiety (e.g., crying, tantrums, freezing, or clinging).</td>
<td>PEL: 1.4</td>
<td></td>
</tr>
<tr>
<td>D - Phobic situation(s) is(are) avoided or faced with intense anxiety or distress.</td>
<td>EDS: 2.3</td>
<td></td>
</tr>
<tr>
<td>F - At least 6 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obsessive-compulsive disorder (OCD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Either obsessions (i.e., repetitive intrusive/inappropriate thoughts, impulses, or attempts to ignore, suppress, or neutralize them with other thoughts or actions) or compulsions (i.e., repetitive behaviors or mental acts, according to rules, and to reduce distress or prevent event).</td>
<td>TAU: 0.1</td>
<td>EDS: 14.5 years</td>
</tr>
<tr>
<td>C - Obsessions/compulsions cause marked distress and are time consuming (&gt; 1 hour a day).</td>
<td>PEL: 0.1</td>
<td></td>
</tr>
<tr>
<td>Posttraumatic stress disorder (PTSD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A - Past exposure to a traumatic event responding with intense fear, helplessness, horror, or disorganized or agitated behavior.</td>
<td>TAU: 0.1</td>
<td>EDS: 22.5 years</td>
</tr>
<tr>
<td>B - Re-experience of the traumatic event through at least one of the following: 1) intrusive recollections of the event or repetitive play of the trauma; 2) dreams of the event or frightening dreams; 3) feeling as if the traumatic event were recurring; 4 and 5) intense psychological distress or physiological reactivity at exposure to internal or external cues that resemble an aspect of the traumatic event.</td>
<td>PEL: 0.1</td>
<td></td>
</tr>
<tr>
<td>C - Avoidance of stimuli associated with the trauma and numbing of general responsiveness, with at least three of the following (not present before the trauma): 1) efforts to avoid thoughts, feelings, or conversations related to the trauma; 2) efforts to avoid activities, places, or people that arouse recollections of the trauma; 3) inability to recall aspects of the trauma; 4) markedly diminished interest or participation in significant activities; 5) feeling of detachment from others; 6) restricted range of affect; 7) sense of a foreshortened future.</td>
<td>EDS: 5.0</td>
<td></td>
</tr>
<tr>
<td>D - Increased arousal (not present before the trauma), with at least two of the following: 1) difficulty falling or staying asleep; 2) irritability or outbursts of anger; 3) difficulty concentrating; 4) hypervigilance; 5) exaggerated startle response.</td>
<td>EDS: 1.3</td>
<td></td>
</tr>
<tr>
<td>E - More than 1 month.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Diagnostic criteria for all anxiety disorders: the focus of the anxiety symptoms is not confined to features of another mental disorder. The anxiety symptoms cause clinically significant distress or impairment in social, family, school, or other important areas of functioning. The disturbance is not due to the effects of a substance, general medical condition, or another mental disorder. EDS = Early Developmental Stages of Psychopathology (Composite - International- Diagnostic Interview - CIDI, lifetime, ages 14-24); GSM = Great Smoky Mountains Study (Child and Adolescent Psychiatric Assessment - CAPA, 3-month prevalence, ages 9-16); NCS = National Comorbidity Survey - Adolescent (CIDI, lifetime, ages 13-18); PEL = Pelotas Study (Development and Well-Being Assessment - DAWBA, current, ages 11-12); TAU = Taubaté Study (DAWBA, current, ages 7-14).
whereas two additional sets of genes might influence risk for two more narrow aspects of illness, reflecting still broad risks for internalizing and externalizing disorders, respectively. Environmental factors generally involve non-shared environment effects; meaning factors that tend to make individuals within a family appear different. Such factors include aspects of an individual child’s school environment, the unique stressors he or she experiences, and their social situation. This is somewhat consistent with the generalist genes, specialist environment model, i.e., that common psychopathology mostly share their genetic liability, but are differentiated by non-shared experiences.

Twin studies that specifically focused on pediatric anxiety also support the role of both genes and environment, but the role of the shared environment also appears to be significant with lower genetic effects. These types of studies focus more narrowly on specific presentations of anxiety, in contrast to studies more broadly examining varieties of psychopathology. These more narrow studies are incapable of specifying what genes and environmental factors are particularly noteworthy for pediatric anxiety. Nevertheless, no twin study is capable of clarifying how any set of genes and environments affects the brain unless the study directly assesses brain function. It is only through effects on the brain that genes and the environment can ultimately result in emotional and behavioral abnormalities. Candidate gene studies search for specific loci at the genome. While these have been criticized as being vulnerable to type I errors, they have identified several risk genes for anxiety disorders, but, consistent with type I errors, a recent review suggested that available work resulted in “not a single instance of replication.” Genome-wide association studies (GWAS) search the entire genome for signs of association. When performed properly, these are less vulnerable to type I errors. To date, five such GWAS have been performed on anxiety disorders, though none of these focuses on children. Among the five, two of them produced significant results. Otowa et al. found two genes that achieved genome-wide significance (transmembrane protein 16B and plakophilin 1), but a subsequent study failed to replicate these findings in PD patients. In another study, a variant in the retinoid-related orphan receptor alpha gene (RORA) showed genome-wide significance for PTSD. In addition to these five GWAS investigations, other studies have investigated the excess of rare copy number variations (CNVs), which are relative large segments of DNA that are either deleted or duplicated. In this area, the only study on PD failed to find genome-wide significance.

While each of these genetic strategies has advantages, they also are relatively insensitive to many mechanisms. For example, available evidence finds signs of complex gene-environment interplay in anxiety disorders, and most research on genetics is poorly suited for capturing such effects. Genes and environments shape anxiety and other behaviors through a complex interplay, as it has been shown through three specific relationships: 1) gene-environment interaction (genetically influenced sensitivity to specific environments); 2) gene-environment correlation (genetic influences on individual variation in people’s exposure to particular environments); 3) epigenetics (environmental moderation of the effects of genes through influences in gene expression). As understanding of genes and the environment accrue, the complexity of these three sets of relationships is likely to appear even greater. This suggests that, for anxiety and other so-called complex behaviors influenced by multiple factors, the effects of genes are far from deterministic and cannot be dissociated from the effects of the child’s environmental conditions. Figure 1 illustrates these complex relationships.

Pathophysiological processes and neural substrate

Despite a considerable advance over the last years, little is known about the neural underpinnings of anxiety disorders in children and adolescents. Most of the work in this area focuses on information processing functions involved in emotional processing (in particular threat processing) and cognitive control. The state of knowledge about mental processes involved in pediatric anxiety is currently limited. Nevertheless, tentative conclusions about existing relationships can be drawn. In particular, a set of dysfunctional mental processes has been linked to pediatric anxiety and associated traits, such as the early-childhood temperament of behavioral inhibition. These dysfunctional processes can be classified into five groups of information-processing functions: 1) threat-attention interaction (a tendency for anxious children to automatically orient their attention towards or away from threats); 2) threat appraisal (a tendency for anxious children to classify and respond to neutral or harmless stimuli as if they are dangerous); 3) memory and learning processes (a tendency for anxious individuals to learn different associations among safe and dangerous stimuli, as presented in fear conditioning and extinction experiments); 4) social evaluative processes (a tendency for anxious children to become concerned about peer evaluation); and 5) increased sensitivity to rewards (a tendency for anxiety children to more strongly alter their behavior when trying to achieve rewards).

This set of findings suggests that anxiety disorders involve dysfunctional processes in various emotional and cognitive processes, each of which is in turn regulated by several brain regions that may support anxiety disorder pathophysiology. Some of the regions include: the amygdala, several portions of the prefrontal cortex - particularly the ventrolateral and dorsomedial divisions - and dysfunctions in the basal ganglia, particularly in patients with OCD.
as well as features that can occur either within or outside of the home, such as stressful life events. Nevertheless, the evidence so far is limited regarding the direction of these associations. For example, one could hypothesize that some parents who are themselves already anxious might also respond to their child’s anxiety or other signs of vulnerability with parenting practices that may further reinforce the child’s difficulties, such as failure to encourage infant social responsiveness. In other words, such environmental factors could either predispose to anxiety in children or children who are at risk for anxiety may behave in such a way that these environmental factors are preferentially elicited. Kender & Baker found that stressful life events, parenting, family, environment, social support, peer interactions, and marital quality are significantly influenced by genetic factors with heritability estimates ranging from 0.07 to 0.39 - suggesting that associations between anxiety and parenting or other environmental factors may be genetically mediated. Other studies found that the effect of parenting was only partially genetically mediated with an important role of non-shared environment. In addition, some authors suggest that some fears may arise as a result of modeling and vicarious learning (i.e., learning through observation of a parent fearful response in a threatening situation for her/him) and verbal transmission of threat information about novel objects. However, more experimental studies are needed to better understand these phenomena.

Research on influences of parenting in psychiatric disorder illustrates that risk and causality in psychiatry are extremely complex phenomena. In addition, heterogeneity within anxiety disorders is an important factor to consider. Two individuals with similar clinical manifestations may have different dysfunctional processes, and the same dysfunctional process may be

Figure 1 Schematic representation of the etiological and pathophysiological process related to anxiety disorders. E1, main environmental effects (E); G1, main genetic effects (G); E2×G2, example of gene environment interaction (GxE; genetic sensitivity to specific environments); E4→G4, example of epigenetic regulation (Epi; environmental regulation of gene expression); E5→G5, example of gene environment correlation (rGE; genetic influences on individual variation in people’s exposure to particular environments). Genes and environments influence the developing brain. Dysfunctional circuits in the neural substrate result in deficient information processing that ultimately affect individuals’ thoughts, emotions, and/or behaviors. Extreme dysfunctions in such system produce functional impairment and are interpreted as anxiety disorders.

Rev Bras Psiquiatr. 2013;35(Suppl 1)
responsible for different clinical manifestations. New initiatives, such as the Research Domain Criteria (RDoC), are attempting to clarify the ways in which underlying neural substrates of mental disorders contribute to dimensional traits that are expressed in specific behaviors and that cut across current operationalization of psychopathology.

Dimensional aspects of anxiety

As noted above, fear and anxiety are adaptive responses to potential threats. The expression of these symptoms can range from normative to pathological behavior according to the frequency, intensity, duration and/or interference in functioning. Therefore, anxiety disorders may lie at the extreme end of a continuum, rather than involve symptoms that are exclusive to pathological conditions. As such, anxiety disorders would represent a variation in degree but not in kind. This would imply a view of normal and pathological anxiety as falling along a dimension, with diagnostic thresholds reflecting clinical and societal burden rather than discontinuous pathological states. If this view of anxiety is correct, it would be quite important to study the normal development of fears and learn to recognize temperaments that are closely related to psychopathology in infants. Two such factors associated with anxiety are behavioral inhibition and anxiety sensitivity.

Normal development of fears

Because the development of fear circuitry occurs early, fear responses can be observed very early in life. There are changes in the context of normative fear over the course of development, typically from immediate and concrete stimuli during infancy to anticipatory, abstract, and more global stimuli that characterize adolescent fears. During infancy and toddlerhood, most infants develop a fear of loss and shyness to strangers that peaks around 8 to 12 months of age, as is expressed by wariness around unfamiliar people. These fears are often followed by separation anxiety that peaks around 10 to 18 months marked by distress about being separated from parents. For most children, those fears disappear around 2 to 3 years of age. Early childhood (pre-school age) is characterized by normative fears related to specific threats, such as meteors, clouds, blood, end of the world, being kidnapped, fairies, loss of orientation, and dying or death of others. School age is marked by similar fears, including those directed towards wind, darkness, water, domestic animals, insects, ghosts, death, and disease, germs, natural disasters, traumatic events, harm to self or others, school anxiety, and performance anxiety. Adolescence is characterized by fear of negative evaluation and fear of rejection from peers. All normative fears typically decrease with age and are transient. In adolescence, stability begins to become apparent. Increases in prevalence of phobic and anxiety disorders parallel decreases in normative fears.

Behavioral inhibition and anxiety sensitivity

Given the dimensional and developmental nature of internalizing psychopathology, researchers have considered whether certain types of temperaments observed very early in life predict later risk for pediatric anxiety. Most of this work has focused on infants who display heightened reactions to novelty and heightened sensitivity to stimulus variations. Some such infants mature to become toddlers who withdraw from novel or unfamiliar social situations. This group of toddlers is said to manifest the temperament of behavioral inhibition. This temperament places the child at risk for SoAD. A recent meta-analysis showed that behavioral inhibition was associated with a seven-fold increased risk for developing SoAD. Given that 15% of infants are classified as behaviorally inhibited and about half of them will develop social anxiety this is one of the most consistent risk factors for social anxiety. Anxiety sensitivity is another dimensionally distributed trait that, like behavioral inhibition, has been linked to pediatric anxiety. Anxiety sensitivity involves beliefs that anxious symptoms will have harmful physical, psychological, or social consequences to the individual. Some studies suggest that this trait predicts PD more specifically than other forms of anxiety, expressed later in life. Although these dimensional traits are often seen as risk factors, an alternative conceptualization is that they represent alternative manifestations of overt anxiety disorders, as they are expressed in younger children.

Clinical manifestations and diagnosis

Despite the dimensional perspective of fear and anxiety, diagnostic and clinical decisions (e.g., to treat or not to treat) are categorical and require a classificatory system. According to the DSM-IV, most of the anxiety disorders have the same diagnostic criteria for children, adolescents or adults, with some minor variations in presentation (Table 1).

Screening

Some researchers argue that screening for anxiety disorder should be universal (applied to every child irrespective of their symptoms). Despite that, from a public health perspective, only targeted screening may be possible, and it is not clear whether universal screening would be in the best interest of patients. Therefore, screening may be most helpful among children who present with complaints about excessive fears, extreme shyness, frequent worries or rituals - some kind of emotional distress.

Diagnostic procedures and differential diagnosis

The diagnosis of pediatric anxiety disorder is based on clinical evaluations. First, normal fears should be differentiated from pathological fears. The best way of doing this is evaluating whether fears are: 1) developmentally
expected or not; 2) appear with intensity, duration, and frequency that is higher than expected for the same age; and 3) whether the fears result in distress and impairment.

Second, pathological fears should not be better explained by co-occurring symptoms of another psychiatric disorder, by a co-occurring medical disease, or due to the influences of use/abuse of alcohol and/or other psychoactive substances (as well as not due to withdrawal). Therefore, it is crucial to investigate the situations and context in which the anxiety symptoms manifest.

Third, primary anxiety should be classified according to the type of anxiety disorder. Anxiety disorders share in common several clinical features, namely dysfunctional cognitions, physical symptoms, and behavioral dysfunctions such as avoidance - one of the core symptomatic characteristics of all anxiety disorders. However, narrowly defined in diagnostic manuals, specific anxiety disorders also exhibit a substantial degree of phenotypic heterogeneity. Each anxiety disorder has a symptomatic signature. For treatment purposes, it is useful to determine the main anxiety disorder as the condition that produces the greatest distress, impairment, and interference in the child's life. Figure 2 describes the core symptomatic features of the main pediatric anxiety disorders.

**Comorbidity**

Pediatric anxiety disorders and other childhood psychiatric conditions frequently co-exist in the same patient, a phenomenon known as comorbidity. In clinically referred samples, comorbidity is often the rule rather than the exception, with more than half of the patients having more than one anxiety disorder. In community samples, anxiety also increases the chance of having additional psychiatric diagnoses such as major depression (odds ratio [OR] = 8.2; 95%CI 5.8-12), ADHD (OR = 3.0; 95%CI 2.1-4.3), and oppositional defiant disorder/conduct disorder (OR = 3.1; 95%CI 2.2-4.6). Anxiety disorders and substance abuse and dependence in childhood appear not to be related, but this comorbidity increase dramatically in adolescents and adults, notably in subjects with social anxiety. Therefore a search for comorbidity is imperative when evaluating children with anxiety. This includes a specific search for symptoms of major depression (including suicidal ideation), substance abuse and dependence, ADHD, and oppositional defiant disorder. Two other conditions that are not necessarily disorders but are rather specific behaviors also frequently present in anxious children. These conditions are selective mutism, which is the failure to speak in specific setting despite full use of language at home, and school refusal, which is the failure to attend to school. The high degree of comorbidity between anxiety disorders, as a group, and depression is clearly notable. In terms of associations between depression and one or another specific anxiety disorder, evidence is mixed in terms of whether associations are particularly strong with specific conditions. Some studies showed particularly strong associations with GAD, potentially reflecting a singular higher order structure for the two conditions. Other findings appear less specific and more strongly reflecting developmental variations.

**Assessment**

A proper assessment of psychiatric symptoms in childhood involves information derived from the child, parents, and teachers. Particularly for anxiety disorders, the child information is extremely valuable. Since some of the symptoms involve emotions, cognitions, and behaviors that may not involve the parent, it is imperative to consider the child’s report. Younger children may have difficulties communicating their symptoms as well as their associated distress and impairments to the physician. In these cases, parental and teacher information may be more valuable, but clinicians still should be vigilant for signs of avoidance expressed by the child. The clinician should be aware that parents often look for help with unexplained physical complaints reflecting heightened arousal (headaches, stomachaches, nausea, vomiting, diarrhea, muscle tension, and difficulty with sleep) that may indicate an underlying pediatric anxiety.

As mentioned above, the diagnosis of any anxiety disorder is clinical. Although several studies link anxiety to various biological or genetic factors, the magnitude of these associations is far too small to be of clinical use when evaluating individual children. Some structured interviews and/or rating scales may be helpful to: 1) screen for anxiety symptoms in non-specialized settings; 2) assess symptom severity; and 3) monitor treatment gains. Table 2 depicts a variety of clinician, self and parent rated instruments that may be useful in research and clinical practice.

**Treatment**

Both medication and psychotherapy are effective in the treatment of pediatric anxiety symptoms. Literature is reviewed below in four specific areas: 1) non-OCD anxiety disorders (SeAD, SoAD, GAD, and PD); 2) OCD; 3) PTSD; 4) SP. Because PD is exceptionally rare in childhood and adolescence, insufficient evidence exists from controlled studies to guide treatment. Therefore, clinical management of PD is often considered as an extension of the currently available evidence for more common and better studied anxiety disorders (e.g., SeAD, SoAD and GAD). SPs are also highly comorbid with other anxiety disorders. When isolated, treatment should use cognitive behavioral therapy (CBT), with exposure to the feared object combined with cognitive techniques during the exposure (whether in vivo, imaginary, or virtual) that facilitate extinction. Too few studies examine efficacy of medication in SP to inform recommendations, probably because CBT, the less invasive interventions, is typically effective. Evidence regarding the treatment of PTSD and other consequences of trauma in children most deeply
examines CBT, where again, evidence of efficacy is strong. Because the few studies examining medication efficacy in pediatric PTSD are generally equivocal, CBT should be the first-line treatment in children presenting with posttraumatic anxiety. Due to a more specialized characterization of the PTSD treatment, this topic will not be further discussed here. Additional information can be found elsewhere.

**Figure 2** Algorithm for the diagnostic assessment of pediatric anxiety disorders (based on Salum et al.). ADHD = attention deficit hyperactivity disorder; ODD = oppositional defiant disorder

---

Medication + psychoeducation

Placebo-controlled clinical trials demonstrate efficacy for selective serotonin reuptake inhibitors (SSRIs; fluoxetine, fluvoxamine, paroxetine, and sertraline) in both pediatric OCD and non-OCD disorders. Some trials also support the use of serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine for non-OCD disorders.
### Table 2: Instruments for the assessment of anxiety symptoms and diagnosis of anxiety disorders in children and adolescents

#### Clinical instruments for the diagnosis of pediatric anxiety

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Rater (informant)</th>
<th>Diagnosis</th>
<th>Estimated time</th>
<th>Diagnostic system</th>
<th>Reliability</th>
<th>Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>K-SADS* (E/PL)</td>
<td>Clinician (C, P, CLIN)</td>
<td>Current/lifetime</td>
<td>--</td>
<td>DSM-IV</td>
<td>TR: 0.80 (current); 0.60 (lifetime)</td>
<td>--</td>
</tr>
<tr>
<td>DAWBA*</td>
<td>Lay/Clinician (C, P, T, CLIN); COMP (C, P, T, CLIN)</td>
<td>Current</td>
<td>30-50 min</td>
<td>DSM-IV; ICD-10</td>
<td>IR: *κ = 0.91 (internalizing)</td>
<td>CONV: 0.13-0.48 (DISC-IV); 0.23-0.48 (CAPA); diagnosed cases probably more severe than DISC-IV and CAPA</td>
</tr>
<tr>
<td>ChIPS*</td>
<td>Clinician (C, P, CLIN)</td>
<td>Current</td>
<td>20-50 min</td>
<td>DSM-IV + Psychosocial stressors</td>
<td>IR: 0.90-1.00</td>
<td>DISCR: higher rate of diagnosis in a clinic than in a community sample (OR = 13.3)</td>
</tr>
<tr>
<td>DISC-IV</td>
<td>Clinician (C, P, CLIN); COMP (C, P, CLIN)</td>
<td>Current</td>
<td>70 min</td>
<td>DSM-IV; ICD-10</td>
<td>TR: 0.48-0.86</td>
<td>CONV: 13-0.48 (DAWBA); 0.21-0.61 (CAPA)</td>
</tr>
<tr>
<td>DICA-IV</td>
<td>Clinician (C, P, CLIN); COMP (C, P, CLIN)</td>
<td>Current</td>
<td>30-120 min</td>
<td>DSM-IV</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>ISCA</td>
<td>Clinician (C, P, CLIN)</td>
<td>Current</td>
<td>45-90 min (C); 120-15 min (P)</td>
<td>DSM-IV</td>
<td>IR: 0.95</td>
<td>--</td>
</tr>
<tr>
<td>ADIS-C</td>
<td>Clinician (C, P, CLIN)</td>
<td>Current</td>
<td>--</td>
<td>DSM-IV (focus on anxiety disorders)</td>
<td>TR: 0.80 to 0.92</td>
<td>--</td>
</tr>
<tr>
<td>CAPA</td>
<td>Clinician (C, P, CLIN)</td>
<td>Current</td>
<td>60 min</td>
<td>DSM-IV; ICD-10</td>
<td>TR: 0.74-0.79</td>
<td>CONV: 0.23-0.48 (DAWBA); 0.21-0.61 (DISC-IV)</td>
</tr>
<tr>
<td>PAPA</td>
<td>Clinician (P, CLIN); COMP (P, CLIN)</td>
<td>Current</td>
<td>100 min</td>
<td>DSM-IV; ICD-10 + RDC-PA; DC: 0-3R</td>
<td>TR: 0.74</td>
<td>--</td>
</tr>
<tr>
<td>CIDI-A</td>
<td>Lay (C); COMP</td>
<td>Current/lifetime</td>
<td>2.5 hours (C)</td>
<td>DSM-IV; ICD-10</td>
<td>--</td>
<td>CONV: Area Under the Curve &gt; 0.79 (KSADS-PL)</td>
</tr>
</tbody>
</table>

#### Rating scales for the assessment of anxiety symptoms within a broad anxiety construct

<table>
<thead>
<tr>
<th>Scale</th>
<th>Rater</th>
<th>Number of items</th>
<th>Estimated time</th>
<th>Reliability</th>
<th>Validity</th>
<th>Cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAI-C*</td>
<td>Self</td>
<td>20 (state) + 20 (trait)</td>
<td>20 min</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>RCMAS*</td>
<td>Self</td>
<td>37</td>
<td>15 min</td>
<td>IC: 0.83-0.85</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>BAI-Y</td>
<td>Self</td>
<td>20</td>
<td>10 min</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

#### Rating scales for the assessment of anxiety symptoms of various anxiety dimensions

<table>
<thead>
<tr>
<th>Scale</th>
<th>Rater (informant)</th>
<th>Items</th>
<th>Estimated time</th>
<th>Dimensions of evaluation</th>
<th>Reliability</th>
<th>Validity</th>
<th>Cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARS</td>
<td>Clinician (C, P, CLIN)</td>
<td>50 + 7-item severity scale</td>
<td>20-30 min</td>
<td>GA; SoA; SeA</td>
<td>IC: 0.64</td>
<td>CONV: 0.61 (CGI-S)</td>
<td>TREAT: 8-10 (84-94%)</td>
</tr>
</tbody>
</table>

*Continued on next page*
Table 2 Continued

Rating scales for the assessment of anxiety symptoms of various anxiety dimensions

<table>
<thead>
<tr>
<th>Scale</th>
<th>Rater</th>
<th>Items</th>
<th>Estimated time</th>
<th>Dimensions of evaluation</th>
<th>Reliability</th>
<th>Psychometric properties</th>
<th>Cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCARED*</td>
<td>Self and parent</td>
<td>41</td>
<td>15 min</td>
<td>GA; PANIC-SOMAT;</td>
<td>IC: 0.90</td>
<td>CONV: 0.81 (MASC)</td>
<td>DX: ≥ 26 (71% SENS; 61-71% SPEC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SeA; SoA; SCHOOL</td>
<td>*IC: 0.90</td>
<td>DIVG: 0.58 (CDI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*TR: 0.86</td>
<td>DISCR: anxiety disorders vs. other psychiatric disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*TR: 0.81</td>
<td>*DX: ≥ 23 (81.8% SENS; 92.0% SPEC)</td>
<td></td>
</tr>
<tr>
<td>SCAS*</td>
<td>Self and parent</td>
<td>38</td>
<td>15 min</td>
<td>GA; PANIC-AG;</td>
<td>IC: 0.92</td>
<td>CONV: 0.71 (RCMAS)</td>
<td>DX: ≥ 40 boys ages 8-11;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SeA; SoA; OC; FEARS</td>
<td>TR: 0.60</td>
<td>DIVG: 0.48 (CDI)</td>
<td>≥ 11; 33 boys ages 12-15;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DISCR: anxiety disorders vs. control</td>
<td>≥ 50 girls ages 9-11;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ 39 girls ages 12-15;</td>
</tr>
<tr>
<td>MASC*</td>
<td>Self and parent</td>
<td>39</td>
<td>15 min</td>
<td>SOMAT; HA; SeA; SoA</td>
<td>IC: 0.90</td>
<td>CONV: 0.63 (RCMAS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.79-0.93</td>
<td>DIVG: 0.19 (CDI)</td>
<td></td>
</tr>
</tbody>
</table>

Rating scales for the assessment of anxiety symptoms of a specific anxiety dimension

<table>
<thead>
<tr>
<th>Scale</th>
<th>Rater</th>
<th>Items</th>
<th>Estimated time</th>
<th>Dimension of evaluation</th>
<th>Reliability</th>
<th>Psychometric properties</th>
<th>Cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSAS-CA</td>
<td>Clinician (C, P, CLIN)</td>
<td>24</td>
<td>--</td>
<td>SoA</td>
<td>IC: 0.95-0.97</td>
<td>CONV: 0.75 (SPAI-C)</td>
<td>DX: ≥ 23 social phobia vs. control (95.9% SENS; 100% SPEC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR with IR: 0.94</td>
<td>DIVG: 0.36 (CDRS-R)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DISCR: social phobia vs. other anxiety disorders and control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPIA-C</td>
<td>Self</td>
<td>26</td>
<td>--</td>
<td>OC</td>
<td>IC: 0.95 / 0.94</td>
<td>DISCR: social phobia vs. control</td>
<td>DX: ≥ 19 (30% FN; 26% SPEC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.55-0.66 / 0.78</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.84</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IR: 0.87-0.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CY-BOCS</td>
<td>Clinician (C, P, CLIN), self and parent</td>
<td>81 + 10-item severity scale</td>
<td>--</td>
<td>OC</td>
<td>IC: &gt; 0.93</td>
<td>DISCR: social phobia vs. control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.84</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IR: &gt; 0.98</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CONV: 0.79 (YBOCS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DIVG: 0.34 (CDI); 0.37 (CMAS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DISCR: low Pearson coefficients with HAM-A, HAM-D, YGTSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSSC-R</td>
<td>Self</td>
<td>80</td>
<td>--</td>
<td>FEARS</td>
<td>IC: 0.94-0.95</td>
<td>CONV: 0.46-0.51 (STAI-C)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TR: 0.55-0.82</td>
<td>DISCR: school phobia vs. control</td>
<td></td>
</tr>
</tbody>
</table>

ADIS-C = Anxiety Disorders Interview Schedule for Children; AG = agoraphobia; BAI-Y = Beck Anxiety Inventory for Youth; C = children as informant; CAPA = Child and Adolescent Psychiatry Assessment; CDI = Children's Depression Inventory; CDRS = Children's Depression Rating Scale; CDRS-R = Children's Depression Rating Scale, Revised; CGI-S = Clinical Global Impression, Severity Scale; CHIPS = Children’s Interview for Psychiatric Syndromes; CIDI-A = Composite International Diagnostic Instrument, Adolescent adaptation; CUN = clinician impression; CY-BOCS = Children Yale-Brown Obsessive-Compulsive Scale; COMP = computer-assisted; CONV = convergent; DAWBA = Development and Wellbeing Assessment; DICA = Diagnostic Interview for Children and Adolescents; DISC-IV = Diagnostic Interview Schedule for Children, Fourth Edition; DISCR = discriminant; DIVG = divergent; DX = criteria to the diagnosis of pediatric anxiety disorders; DYBOCS = Dimensional Yale-Brown Obsessive-Compulsive Scale; FEARS = specific phobias; FSSC-R = Fear Survey Schedule for Children, Revised; GA = generalized anxiety; FN = false negatives; FP = false positives; HA = harm avoidance; HAM-A = Hamilton Anxiety Rating Scale; HAM-D = Hamilton Depression Rating Scale; IC = internal consistency; IR = interrater; ISCA = Interview Schedule for Children and Adolescents; K-SADS-E = Schedule for Affective Disorders and Schizophrenia for School-Age Children, Epidemiologic Version; K-SADS-PL = Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present and Lifetime Version; LOI-CV = The Leyton Obsessional Inventory, Child Version Survey Form; LSAS-CA = Liebowitz Social Anxiety Scale for Children and Adolescents; MASC = Multidimensional Anxiety Scale for Children; OC = obsessions-compulsions; OCD = obsessive-compulsive disorder; P = parent as informant; PAPA = Pre-School Age Psychiatric Assessment; PANIC = panic attacks; PARS = Pediatric Anxiety Rating Scale; RDC-PA = Research Diagnostic Criteria, Preschool Age; SCARED = Screen for Child Anxiety Related Emotional Disorders; SCAS = Spence Children's Anxiety Scale; SCHOOL = school phobia; SeA = separation anxiety; SENS = sensitivity; SOMAT = somatic/physical symptoms; SoA = social anxiety; SPAI-C = Social Phobia and Anxiety Inventory for Children; SPEC = specificity; STAI-C = State-Trait Anxiety Inventory for Children; T = teacher as informant; TR = test-retest; TREAT = criteria to remission/response to treatment; Y-BOCS = Yale-Brown Obsessive-Compulsive Scale; YGTSS = Yale Global Tic Severity Scale.

* Instrument with published reference of translation/cross-cultural adaptation to Brazil and psychometric properties of the Brazilian version; -- Information not available or restricted to the instrument's manual.
Regarding tricyclic antidepressants (TADs), one placebo-controlled study supported the effectiveness of clomipramine in the treatment of OCD,\textsuperscript{159} as did two studies in children with school refusal.\textsuperscript{30} The magnitude of medication response can be quantified using various metrics. The so-called number-needed-to-treat (NNT) is emerging as a current standard. With this metric, estimates are that approximately four patients should be using the aforementioned drugs in the anxiety disorders treatment in order to one to achieve clinical response rates (n=14 studies/2,102 patients; medication 58.1% vs. placebo 31.5%; RR = 1.9; NNT = 4).\textsuperscript{158} This represents a very strong, robust clinical effect, relative to other conditions. For example, the NNT in either pediatric or adult depression for most medication treatments is not half as potent. There is evidence of the decrease in all anxiety symptoms with these medications. There is no direct evidence that any of these medications offer better responses to treatment or are better tolerated.\textsuperscript{158} However, a mixed comparison meta-analysis found that between SSRIs and venlafaxine, venlafaxine was less efficacious than fluvoxamine and paroxetine and less tolerated than fluvoxamine, paroxetine, and sertraline.\textsuperscript{160}

Besides the SSRIs and venlafaxine, three studies about the use of imipramine among patients with anxiety disorders have demonstrated its effectiveness in non-OCD disorders.\textsuperscript{161} However, TADs are considered secondary choices due to their less favorable adverse effects and the fact that they require continuous monitoring of blood and cardiac irregularities.\textsuperscript{158} There is no evidence supporting the use of benzodiazepines in the treatment of pediatric anxiety disorders.\textsuperscript{162}

It is vital to emphasize that psychoeducation is an essential part of the treatment of anxiety disorders. Psychoeducation includes the explanation of the characteristics of the symptoms, course, treatment strategies, potential side effects, duration of treatment, etc. Moreover, it is critical to verify that the patient is using the medication adequately. More frequent visits in the beginning of the treatment (weekly, fortnightly) or a phone-based follow-up are good alternatives to ensure and increase treatment compliance. An algorithm to choose among the therapeutic options is depicted in Figure 3. The most used first-line medications in the treatment of anxiety disorders, their usage, and adverse effects are shown in Table 3.

**Psychotherapy**

CBT is the approach with stronger evidence of effectiveness as compared to waiting lists or attention control interventions for both OCD\textsuperscript{163-165} and non-OCD pediatric anxiety disorders.\textsuperscript{164-166} The overall effect size of CBT for pediatric anxiety in a meta-analysis involving 48 studies (n=3,740) was 0.66 (compared to passive control 0.77 and to active control 0.39; both significant), demonstrating a key role of non-specific factors.\textsuperscript{164} The effect size for non-CBT interventions was not significant.\textsuperscript{164} Treatment target CBT (specific to one anxiety disorder) and individual treatments (as opposed to groups) had a larger effect size than treatment targeting several anxiety disorders and group CBT.\textsuperscript{164} Clinical trials have also shown that CBT may have better results for treating OCD when family members are involved to reduce the levels of family accommodation (the different ways that family members may respond to the patient's symptoms by facilitating avoidance, assisting on ritualistic behaviors, or inadvertently participating in rituals).\textsuperscript{167}

**Combined treatment**

Two large studies have evaluated the combined treatment as compared to the monotherapy and placebo components.\textsuperscript{108,168} For non-OCD anxiety disorders, the CBT+sertraline combined treatment was more effective than both monotherapy conditions and the placebo condition.\textsuperscript{108} For OCD, the combined treatment was more effective than the serotonin monotherapy and the placebo conditions, but there was no difference between the combined treatment and the CBT monotherapy.\textsuperscript{168} Data from this study investigating moderator factors of these therapy conditions have demonstrated that, for patients with a family history of OCD, the combined treatment or the sertraline monotherapy condition are preferable.\textsuperscript{169} Conversely, for patients with comorbid OCD and tic disorders - a frequent comorbidity -, the combined treatment or the CBT are preferable.\textsuperscript{170} Moreover, in these cases, the combination of SSRI and alpha-adrenergic agonists or anti-psychotics might be an option.\textsuperscript{171}

**Other treatments and future perspectives**

Innovative treatments for anxiety disorders have been developed from the neuroscience field, such as the d-cycloserine combined with behavioral techniques\textsuperscript{172} and the attentional bias modification treatment.\textsuperscript{173,174} Regulators of glutamatergic neurotransmission, such as rituxol\textsuperscript{175} and N-acetylcysteine,\textsuperscript{176} have also been examined in adolescents diagnosed with OCD. Although promising, these treatments do not yet present long-term outcomes and are currently restricted to research settings.

Studies in adults and children have demonstrated that interventions focusing on the individual’s lifestyle, such as physical exercise, are associated with improvements in anxiety and depressive symptoms,\textsuperscript{177-179} and exercise should be encouraged. Evidence from studies with adult samples have also stated that complementary treatments with kava,\textsuperscript{180} valerian,\textsuperscript{181} passiflora,\textsuperscript{182} meditation,\textsuperscript{183} or healing touch\textsuperscript{184} have inconclusive benefits in the treatment of anxiety disorders, with not enough evidence to recommend their use.

**Monitoring, refractoriness, referring**

Due to the unfavorable natural history of anxiety disorders, it is highly important to monitor anxiety symptoms and potential side effects objectively and systematically.\textsuperscript{185} Some studies have suggested that SSRI treatments might lead to an increase in suicidality among children. Further
Figure 3 Algorithm for the management of pediatric anxiety disorders (based on Salum et al. 107). CBT = cognitive behavioral therapy; GAD = generalized anxiety disorder; OCD = obsessive-compulsive disorder; PD = panic disorder; PTSD = posttraumatic stress disorder; SeAD = separation anxiety disorder; SoAD = social anxiety disorder; SP = specific phobias; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor
### Table 3: Main drugs used in the treatment of pediatric anxiety disorders

**SSRI**

<table>
<thead>
<tr>
<th>Drug (GRADE)</th>
<th>Indications: non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</th>
<th>Contraindications: MAOI use, pimozide use, hypersensitivity to the drug</th>
<th>Most common adverse effects of the class: nausea, headache, drowsiness, insomnia, dizziness, increased appetite, abdominal pain, nervousness, aggressive behavior, impulsivity, irritability, increased appetite, increased weight, decreased appetite, abdominal pain, nausea, vomiting, diarrhea, constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, abnormal platelet aggregation, CYP2D6 and CYP3A4 inhibition.</th>
<th>Fluoxetine (B)</th>
<th>Johns Hopkins University School of Medicine.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SSRI</strong></td>
<td><strong>Indications:</strong> non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</td>
<td><strong>Contraindications:</strong> MAOI use, pimozide use, hypersensitivity to the drug</td>
<td><strong>Most common adverse effects:</strong> nausea, headache, drowsiness, insomnia, dizziness, increased appetite, abdominal pain, nervousness, aggressive behavior, impulsivity, irritability, increased appetite, increased weight, decreased appetite, abdominal pain, nausea, vomiting, diarrhea, constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, abnormal platelet aggregation, CYP2D6 and CYP3A4 inhibition.</td>
<td><strong>Fluoxetine (B)</strong></td>
<td><strong>Recommendation:</strong> start with a single dose of 5 mg/day in the morning meal for 1 week, increase to 10 mg/day and wait for therapeutic response (4-6 weeks), with increases in dose (+10 mg/day each week) according to clinical response and tolerance until the maximum dose of 20-30 mg/day, according to age and weight.</td>
</tr>
<tr>
<td><strong>SSRI</strong></td>
<td><strong>Indications:</strong> non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</td>
<td><strong>Contraindications:</strong> MAOI use, pimozide use, hypersensitivity to the drug</td>
<td><strong>Most common adverse effects:</strong> nausea, headache, drowsiness, insomnia, dizziness, increased appetite, abdominal pain, nervousness, aggressive behavior, impulsivity, irritability, increased appetite, increased weight, decreased appetite, abdominal pain, nausea, vomiting, diarrhea, constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, abnormal platelet aggregation, CYP2D6 and CYP3A4 inhibition.</td>
<td><strong>Paroxetine (C)</strong></td>
<td><strong>Recommendation:</strong> start with a dose of 10 mg/day at night meals (no chewing), increase to 20 mg/day and wait for therapeutic response (4-6 weeks), with increases in dose (+25 mg/day each week) according to clinical response and tolerance until the maximum dose of 50 mg/day/day, according to age and weight.</td>
</tr>
<tr>
<td><strong>SSRI</strong></td>
<td><strong>Indications:</strong> non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</td>
<td><strong>Contraindications:</strong> MAOI use, pimozide use, hypersensitivity to the drug</td>
<td><strong>Most common adverse effects:</strong> nausea, headache, drowsiness, insomnia, dizziness, increased appetite, abdominal pain, nervousness, aggressive behavior, impulsivity, irritability, increased appetite, increased weight, decreased appetite, abdominal pain, nausea, vomiting, diarrhea, constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, abnormal platelet aggregation, CYP2D6 and CYP3A4 inhibition.</td>
<td><strong>Sertraline (A)</strong></td>
<td><strong>Recommendation:</strong> start with a single dose of 25 mg/day in the morning meal for 1-2 weeks, increase to 50 mg/day and wait for therapeutic response (+25 mg/day each week) according to clinical response and tolerance until the maximum dose of 100 mg/day/day, according to age and weight.</td>
</tr>
<tr>
<td><strong>SNRI</strong></td>
<td><strong>Indications:</strong> non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</td>
<td><strong>Contraindications:</strong> hypersensitivity to MAOI</td>
<td><strong>Most common adverse effects:</strong> nausea, vomiting, diarrhea, Constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, complex metabolization (substantially affects metabolism of other drugs: [CYP2D6] and [CYP3A4]), frequent withdrawal syndrome. Increase in blood pressure, and withdrawal syndrome.</td>
<td><strong>Venlafaxine IR (D)</strong></td>
<td><strong>Recommendation:</strong> start with a dose of 37.5 mg/day for 1 week, increase to 75 mg/day and wait for therapeutic response (4-6 weeks), with increases in dose (+37.5 mg/day each week) according to clinical response and tolerance until the maximum dose of 225 mg/day/day, according to age and weight.</td>
</tr>
<tr>
<td><strong>SNRI</strong></td>
<td><strong>Indications:</strong> non-OCD anxiety disorders (GAD, SoAD, SeAD) + PD and OCD</td>
<td><strong>Contraindications:</strong> hypersensitivity to MAOI</td>
<td><strong>Most common adverse effects:</strong> nausea, vomiting, diarrhea, Constipation, dry mouth, sweating, tremor, decreased sexual desire, delayed ejaculation, anorgasmia, restlessness, asthenia, complex metabolization (substantially affects metabolism of other drugs: [CYP2D6] and [CYP3A4]), frequent withdrawal syndrome. Increase in blood pressure, and withdrawal syndrome.</td>
<td><strong>Venlafaxine XR (C)</strong></td>
<td><strong>Recommendation:</strong> start with a single dose of 75 mg/day for 2 weeks, increase to 150 mg/day and wait for therapeutic response (4-6 weeks), with increases in dose (+75 mg/day each week) according to clinical response and tolerance until the maximum dose of 300 mg/day/day, according to age and weight.</td>
</tr>
</tbody>
</table>

**References:** UpToDate Online Pediatric Drug Information (http://www.uptodate.com). Evidence was evaluated through the GRADE quality system (A = high; B = moderate; C = low; D = very low).
studies have demonstrated that the benefits of treating anxiety disorders largely outweigh the potential risks related to the increase of suicidal ideation, which, although serious, is a rare event in the treatment of patients with anxiety disorders.\textsuperscript{186} Nevertheless we underscore the need to monitor continuously suicidal thoughts and suicidal behaviors in this population.

There is a lack of consistent evidence regarding the best way to deal with refractory anxiety disorders or the best sequence of treatments to be applied. Overall, the recommendation is to optimize the medication dosage, since some patients only respond at higher doses (e.g., slow metabolizers, OCD patients). If there is no response after 4 to 6 weeks of treatment and after the dosage optimization, it is possible to: 1) change medications within the same class (e.g., fluoxetine for sertraline) or 2) change the previous medication for another one from a different class (e.g., fluoxetine for venlafaxine).\textsuperscript{187}

In public health systems, specialized treatment is recommended in cases in which: 1) patients have shown refractoriness to two previous therapeutic alternatives; 2) patients have severe chronic disorders, including high level of impairment, unusually frequent avoidance behaviors and agoraphobia that do not respond to psychotropic and clearly require behavioral therapy or CBT; and 3) patients present persistent suicidal ideation.

\textit{Preschool children treatment and prevention}

Most of the currently available evidence regarding the treatment of pediatric anxiety disorders is based on studies with school-aged children. However, there is a current trend to offer treatment for younger children (preschoolers), hoping that earlier diagnoses may prevent later psychiatric disorders. Parental training with CBT protocols and the treatment of mood and anxiety disorders in clinically-ill parents are suggested by some authors.\textsuperscript{188} Although scarce, there is promising evidence that treatments based on existing therapies (CBT, parental training, and pharmacotherapy), adapted to at-risk populations, i.e., highly symptomatic children, but still not meeting criteria for the diagnosis of anxiety disorders, or children with first-degree relatives diagnosed with anxiety disorders, result in preventing and reducing the severity of these disorders.\textsuperscript{189}

This is a general overview about pediatric anxiety disorders. More specific and comprehensive reviews about the following topics can be found in the literature: prevalence,\textsuperscript{15,18-20} behavioral inhibition,\textsuperscript{190-192} behavioral genetics,\textsuperscript{48,52} genetics,\textsuperscript{55,56,193,194} gene vs. environment interplay,\textsuperscript{52,70} pathophysiology,\textsuperscript{31,7f} neural substrates,\textsuperscript{71} normal development of fears,\textsuperscript{91} psychopharmacological treatment,\textsuperscript{196-198} and CBT.\textsuperscript{164,199-201}

\textbf{Conclusions}

Anxiety disorders are prevalent, associated with a number of negative life outcomes, and currently under-recognized and under-treated. The etiology involves both genes and environmental factors in a complex interplay. Pathophysiology is still in its infancy, but some brain regions such as the amygdala and the prefrontal cortex potentially play a key role to explain individual differences related to fear and anxiety. The diagnosis is clinical and involves clinical interviews with the child, parents, and teachers. Treatment is effective using medication, CBT, or a combination of strategies.

\textbf{Disclosure}

Giovanni Abrahão Salum receives a post-doctoral fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS). Diogo Araújo DeSouza receives a doctoral fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Maria Conceição do Rosário receives research support from Brazilian government institutions (CNPq) and has worked in the last 5 years as a speaker for the companies Novartis and Shire. Daniel Pine declares no potential conflicts of interest. Gisele Gus Manfro receives research support from Brazilian government institutions (CNPq, FAPERGS and Fundo de Incentivo à Pesquisa - Hospital de Clínicas de Porto Alegre - FIPE-HCPA).

\textbf{References}


Rev Bras Psiquiatr. 2013;35(Suppl 1)


193 Smoller JW, Block SR, Young MM. Genetics of anxiety disorders: the complex road from DSM to DNA. Depress Anxiety. 2009;26:965-75.


